Table 3.
A further meta-analysis with respect to PANSS scores, including only the patients who were not on high-dose antipsychotic prescriptions before participating in the study (with at least 6 weeks at a dose equivalent to 1,000 mg/day chlorpromazine)
| Outcome | Comparison | n | SMD | 95% CI | P-value | I2 (%) |
|---|---|---|---|---|---|---|
| PANSS total score | BRE 4 mg vs placebo | 904 | −0.34 | −0.47, −0.20 | <0.00001 | 0 |
| BRE 2 mg vs placebo | 913 | −0.29 | −0.45, −0.12 | 0.0005 | 34 | |
| BRE 4 mg vs BRE 2 mg | 905 | −0.05 | −0.19, 0.09 | 0.51 | 13 | |
| PANSS positive score | BRE 4 mg vs placebo | 904 | −0.22 | −0.40, −0.03 | 0.02 | 49 |
| BRE 2 mg vs placebo | 913 | −0.15 | −0.33, 0.02 | 0.08 | 42 | |
| BRE 4 mg vs BRE 2 mg | 905 | −0.07 | −0.20, 0.06 | 0.27 | 0 | |
| PANSS negative score | BRE 4 mg vs placebo | 904 | −0.30 | −0.43, −0.17 | <0.00001 | 0 |
| BRE 2 mg vs placebo | 913 | −0.28 | −0.42, −0.13 | 0.0001 | 16 | |
| BRE 4 mg vs BRE 2 mg | 905 | −0.02 | −0.15, 0.11 | 0.71 | 0 |
Abbreviations: 95% CI, 95% confidence interval; BRE, brexpiprazole; PANSS, Positive and Negative Syndrome Scale; SMD, standardized mean difference.